$LLY with a Bullish outlook following its earnings #Stocks The PEAD projected a Bullish outlook for $LLY after a Negative over reaction following its earnings release placing the stock in drift C with an expected accuracy of 77.78%.
LLY trade ideas
Looks Like A Roof! I do not see this pattern often (like maybe 2 other times that I remember) so I googled it and T. Bulkowski (the best chart analyst I have ever followed) had some information online about a "Roof" pattern. I do not see 2 triangles attached to each other at the wide ends which would make a diamond top, but you may see things differently.
T. Bulkowski did not say if it was bullish or bearish, only that it performed poorly statistically among other chart patterns. So I will watch this and maybe learn from it, but to me it resembles a version of a H&S without distinctive peaks for the head or the 2 shoulders.
There are so many rising wedges under this stock that span over the last 2 years that it would be impossible to draw them all, so I will refer to the lowest wedge which would take this under 200 if the bottom trendline were to be broken. Rising wedges are not valid until the bottom line is broken, but when they are broken expect a pull back due to the over-supply inside the wedge..
Price is well above the.236 of the trend up.
LLY is priced for perfection. Not one little thing can be out of place when you are perfect.
No recommendation.
LLY daily - bullish after breakoutLLY daily - is in the bull flag which could be nice and could be bullish if the price breaks out through the upper blue dotted line.
Volume decreased last two days which is bearish because the price went up at a lower volume. Price is moving around 8, 20, and 50 days MA which could indicate a strong move pretty soon.
RSI is neutral.
MACD histogram tick is smaller while the MACD line turns and starts to move up which could be bullish if continue to do so. It also has small bullish divergences.
Overall: LLY could have a strong up move if it moves very strongly above the upper blue dotted line and close there. Long trade would be triggered if the price moves strongly on a bigger volume than the last 20 days' average volume, or if the day is closed above that dotted trend line.
Have in mind that it also looks like an SHS reversal pattern, therefore, I said LLY needs a powerful move for a long position.
LLY is a strong/bulling fundamental stock therefore would be traded only long.
LLY going lower Healthcare has been a safe bet this past year and is starting to look weak across the board. The sector is usually defensive, but it feels overbought. Should see continued selling.
Short term PT: $320
SHORT LLY: OVER VALUED - REV AND EARNINGS GROWTH NEGATIVE trading 50x earnings. negative earnings and rev growth. MAX short. stops 380 2x consecutive daily closes ABOVE. upside 20-30%
LLY testing overhead resistance, supported by 50 dayEli Lilly & Co continues its grind higher despite overall market conditions. Price recently tested overhead resistance and is being supported by its 50 day MA.
Does it belong at these prices?It’s pretty much has gone straight up for the last few years probably won’t be on my list right now good space but they will need some major innovation in the drug space to keep these prices or raise their prices on the drugs they have now :-)
LLY - be careful - $428 is topsLLY is running in to the top of the very long trendline starting in 2013.
Watch for resistance near $395 and $428. $428 will have significant reaction to the downside.
Current price at $370 has probable cause to take a pause maybe toward $334 before resuming the upward trend toward $428 Fib level of 55
LLY Medium Term TrendMany signs point to LLY going up in the next 3-6 months, I personally am a strong believer that it will go up however as seen b historical data it just go with long bull and long bear/flat trends, my target is $380 atm, but for the upcoming recession and down turn I would expect $200-$250 flatline for a few months to possibly a year.
LLY | LongThis week a Twitter user bought a blue tick by spending $8 to post a fake tweet "insulin will be free now". Major Insulin producer LLY erased $30 billion in market cap. in a single day. Fundamentally this stock has a huge P/E ratio, in spide, there still has growth potential for that underlying. IMO LLY will retest new highs.
$LLY with a Bullish outlook following its earnings #Stocks The PEAD projected a Bullish outlook for $LLY after a Negative over reaction following its earnings release placing the stock in drift C with an expected accuracy of 75%.
BUY every dips for LLYEarning reports:
Eli Lilly (NYSE:LLY) Q3 results beat analysts' estimates but the company lowered its FY22 outlook. Q3 non-GAAP EPS rose +12% Y/Y to $1.98, while revenue increased +2.5% Y/Y to $6.94B. The company said the revenue growth was driven by a 14% increase in volume, partially offset by a 7% decline due to lower realized prices and a 4% decrease from unfavorable impact of foreign exchange rates. Sales of diabetes therapies Trulicity rose +16% Y/Y to $1.85B, and Jardiance +47% to $573.3M. New drug Mounjaro for type 2 diabetes saw sales of $187.3M. Revenue from COVID-19 antibodies grew +78% Y/Y to $386.6M. Meanwhile, Olumiant sales fell -55% to $182.9M. Breast cancer drug Verzenio sales increased +84% Y/Y to $617.7M. Cancer therapy Retevmo revenue grew 21% to $40.5M. Gastric cancer drug Tyvyt sales fell -39% Y/Y to $76.8M. Meanwhile, Migraine drug Emgality revenue grew +20% Y/Y to $168.5M.
However, sales of chemotherapy Alimta declined -74% Y/Y to $119.4M. Revenue from Forteo, which is used to treat postmenopausal women who have osteoporosis, declined -12% Y/Y to $177.1M. Lilly added that revenue in the U.S. increased 11% to $4.42B, but revenue outside the U.S. fell 9% to $2.52B. Gross margin as a percent of revenue was 77.3%, a decrease of 1.6 percentage points compared with Q3 2021. Q3 research and development expenses increased 6% Y/Y to $1.80B.
Outlook:
Lilly said it now expects 2022 revenue to be between $28.5B and $29.0B (prior outlook provided during Q2 results was $28.8B to $29.3B) consensus $28.76B. The company said the new revenue outlook includes an additional $300M unfavorability from foreign exchange rates since its previous guidance, for a total impact of ~$1B for the full year. Lilly now anticipates non-GAAP EPS to be between $7.70 and $7.85 (prior outlook $7.90 to $8.05) consensus $7.95. GAAP EPS is expected between $6.50 to $6.65 (prior range $6.50 to $6.65). The company said the reductions in the reported and non-GAAP EPS ranges reflect the unfavorable impact of foreign exchange rates and $0.06 EPS impact linked with acquired IPR&D and development milestone charges in Q3 2022.
Fundamental:
Eli Lilly and Company (NYSE:LLY) is one of the leaders in the treatment of diabetes and obesity and is committed to expanding its presence in the treatment of cancer and autoimmune diseases. In the past, the company showed significant growth in revenue, EBITDA, and margins, which attracted institutional investors and contributed to the increase in the company's capitalization. Mr. Market is capitalizing on FDA approval and Medicare's positive decision on donanemab, which is being investigated in phase 3 clinical trial. However, the controversial efficacy results and the negative safety profile shown in phase 2 call into question the objectivity of assessing the prospects of this medicine. Financial indicators that are significantly higher than the average values of the pharmaceutical industry, declining revenue, a relatively small number of product candidates in Phase 2/3 clinical trials, will be one of the reasons for the start of a corrective movement in the company's shares. And you can also find a lot of articles on market says they are waiting for "The Correction". Possibly I will say no, buy every dip!
Technical:
The trendline support and resistance is from weekly basis, and since 8&21 MAs already catching up on daily basis, therefore, there's no reason that we say it is the top of the LLY, because I could not see the uptrend is end right here. Keep making new highs are always scary, however, if LLY can keep deliver the good financial result, why it can not making another new high? Can we see any down pressures? Therefore, from trend trading side of view, buy every dips if trend still there.
The investments and idea published may not be suitable for all investors. If you have any doubts as to the merits of an investment, you should seek advice from independent financial advisor or other professionals to determine what may be best for your individual needs. We do not and cannot guarantee that your use of our APP and/or any of its features will generate profits. All opinions, news, reviews, research, analysis, prices, or other information contained on or provided via this site are provided on an “as is” basis as general market commentary and/or expressions of opinion only. Information may not be complete, accurate or up to date and may not be suitable for every individual, nor be a suitable basis for an investment decision. No representation, warranty, undertaking, assurance or guarantee (express or implied) is made or given as to the availability, adequacy, accuracy, completeness, reasonableness or appropriateness of any of the information or opinions provided or expressed on or through this site. There is no obligation to notify you of any corrections or modifications.
Eli lilly Pre earnings If parabolic was a stock.
This is exactly how Adobe and Google looked in late 2021 before they lost half of their value.
White lines - Primary trend
Yellow lines - Super uptrend.
2023 will be rough for this one, as all stock return to their primary trendline.. But for now I'll settle for a pullback to yellow support line around 320
LLYthe health services and health technology sectors were the first to receive investment and bullish speculative pressures as the dollar fell
that is, drugs and vaccines never go into crisis .. even LLY has never even dropped below the 200 daily moving average this year, like very few stocks
and has now confirmed a bullish symmetrical triangle, I buy now and on GAP 343 retracement
LLY One-Day Reversal?double speculation?
on 21 September false BO on Descending Triangle (final phase of the Rounding Top) and yesterday One-Day Reversal
LLY daily indecision candle overpriced at all time highOrder SELL LLY NYSE Stop 325.50 LMT 325.50 will be automatically canceled at 20230101 00:00:00 EST
LLY daily indecision candle overpriced at all time high retest gap with exhaustion volume.
Descending TriangleThis one broke to the upside and also broke the resistance of the rectangle.
There must have been a good news event but I am not sure.
I guess we just never know!
No recommendation.
This breakout is almost exactly the height of the wide end of the triangle so far. It could go higher but measuring the wide end and projecting it from the point of the breakout is a one way to guesstimate a target
RectangleDescending triangle that is neutral until a trendline is broken.
The Rectangle is also a neutral pattern.
Upgraded by analysts.
Also a possible H&S pattern.
No recommendation
$LLY Setting up Nicely for a Call$LLY Bouncing off 302 (.681) Fibonacci. Trendsi indicators are almost connecting for a call opportunity. Green EMA (Middle line), Money Momentum flowing right on top of the EMA. As well the RSI right at 40. Waiting for the Buy Signal to confirm movement to the upside. Even with Powell speech, LLY was not really affected by it. Still trading within its zone when the Fibonacci was place back in 16 June 2022.
LLY , LONGTook a B1 in LLY near close
Above its GLB
in lower third of uptrend channel
50 sma takeback today ( my cue)
Morning starish reversal pattern aug 10-13 followed by WP through 10/21 ema's
Entry 317.16
Stop - 309.38
PT1 - 324.93 , sell 1/4 , stop up to half
PT1 - 332.71 , then add mode ~
Eli Lilly and CompanyEli Lilly and Company
Price 301.17 P/E (Trailing) 48.61
Change -3.44 P/E (Forward) 32.37
Change % -1.13% Dividend Yield 1.29%
Prev Close 304.61 Dividend 3.92
Volume 2,198,663 Market Cap 293.72B
Year Low 220.20 EPS (Trailing) 6.27
Year High 335.33 EPS (Forward) 9.41
